Monoclonal Anti- Apolipoprotein A1, APOA1 Antibody

CatalogNo.: BMA1006
Size: 100 μg
Host: Mouse
Reactivity: Human
Isotype: IgG
Application: WB, IHC-P, ICC, Flow-Cyt
Price: $180.00


Catalog# BMA1006

Lot # Check on the product label

Size 100 μg

Isotype IgG1

Clone # N47-7

Host Mouse

Reactivity Human

Product Form Liquid

Purification Protein A purified


A synthetic peptide (conjugated with KLH) corresponding to the region of human APOA1.

Recommend Application

Western Blot, WB (1:200-1:500)

Immunohistochemistry, IHC-P(1:20-1:100)

Immunocytochemistry, ICC (1:20-1:100)

Flow Cytometry, Flow-Cyt (1:20-1:50)

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 40% Glycerol and 0.05% Sodium Azide.

Storage Instruction 

Store at 4°C after thawing (1 week). Aliquot and store at -20°C for long term (at least one year).

Avoid repeated freeze and thaw cycles.


Apolipoprotein A-I (APOA1) is the major protein component of high density lipoprotein (HDL) in plasma. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. It was composed of an N-terminal 4-helix bundle with a hydrophobic core and 2 C-terminal helices. It has an approximate molecular weight of 28 KDa. A G/A polymorphism in the promoter of the ApoA-I gene has been associated with the age at which patients presented with Alzheimer disease. Protection from Alzheimer disease by ApoA1 may rely on a synergistic interaction with alpha-tocopherol.


1. Breslow, J. L., Ross, D., McPherson, J., Williams, H., Kurnit, D., Nussbaum, A. L., Karathanasis, S. K., Zannis, V. I. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc. Nat. Acad. Sci. 79: 6861-6865, 1982.

2. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ (january 2008). "Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery". Nature Reviews Drug Discovery 7 (1): 84–99.

3. Ajees, A. A., Anantharamaiah, G. M., Mishra, V. K., Hussain, M. M., Murthy, H. M. K. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc. Nat. Acad. Sci. 103: 2126-2131, 2006.

4. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kölsch H (2005). "APOA1 polymorphism influences risk for early-onset nonfamiliar AD". Ann. Neurol. 58 (3): 436–41.

5. Maezawa I, Jin LW, , Montine TJ, Montine KS (2004). "Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity". J. Neurochem. 91 (6): 1312–21.